Robert Bell | BiotechTV

top of page

ASGCT 2026: Ascidian Therapeutics is presenting initial human safety data from its RNA exon editing platform in a Stargardt disease trial

CSO Robert Bell describes the advantages of RNA exon editing he sees over DNA editing, and walks us through the safety data. With that in hand, which was in adult patients, the company is moving forward in pediatric patients. Coverage brought to you by

Company News

13 hours ago

Ascidian presented NHP and human retinal explant data at #ASGCT2024 suggesting proof of concept for its RNA exon editing approach

Head of research Robert Bell described the preclinical data in a Stargardt disease model that has led to an IND acceptance for this...

Company News

May 9, 2024

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

HSBC Innovation Banking's dedicated sector experts possess in-depth knowledge of the technology, life science and healthcare economies. With access to an extensive global network, we can help you fuel growth through venture capital and corporate investors, industry influencers, customers, and global opportunities.

Through our interconnected innovation hubs in the US, UK, Israel and Hong Kong, our experts are supporting the world’s innovation economy – both clients and their investors to help them meet their growth goals.

Learn more

bottom of page

ASGCT 2026: Ascidian Therapeutics is presenting initial human safety data from its RNA exon editing platform in a Stargardt disease trial

Ascidian presented NHP and human retinal explant data at #ASGCT2024 suggesting proof of concept for its RNA exon editing approach

Follow BiotechTV

Sponsors

Sponsor Spotlight